Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 446.50 |
| Open | 446.35 |
| Bid | 448.70 x 0 |
| Ask | 449.25 x 0 |
| Day's range | 444.40 - 449.25 |
| 52-week range | 400.20 - 467.90 |
| Volume | 2,120,902 |
| Avg. volume | 2,254,977 |
| Market cap | 1.036T |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 24.94 |
| EPS (TTM) | 18.01 |
| Earnings date | N/A |
| Forward dividend & yield | 9.10 (2.03%) |
| Ex-dividend date | 26 Mar 2021 |
| 1y target est | 326.96 |
- Globe Newswire
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 12 April 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme initiated 3 February 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 3 February 2021 to 3 May 2021. Since the announcement as of 29 March 2021, the following transactions have been made: Number ofB sharesAveragepurchase priceTransactionvalue, DKKAccumulated, last announcement4,251,974 1,887,954,18229 March 2021110,000429.2147,212,95830 March 2021110,000431.5247,467,35931 March 2021130,000433.5956,366,4196 April 2021115,000428.2349,246,7777 April 2021115,000427.1249,118,6818 April 2021120,000431.9051,827,4829 April 2021115,000436.8350,235,640Accumulated under the programme5,066,974 2,239,429,497 The details for each transaction made under the share repurchase programme are published on novonordisk.com. With the transactions stated above, Novo Nordisk owns a total of 43,969,586 B shares of DKK 0.20 as treasury shares, corresponding to 1.9% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares. Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 3 February 2021. As of 9 April 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 5,066,974 B shares at an average share price of DKK 441.97 per B share equal to a transaction value of DKK 2,239,429,497. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Media: Anne Margrethe Hauge+45 3079 3450amhg@novonordisk.comMichael Bachner (US)+1 609 664 7308mzyb@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.comValdemar Borum Svarrer+45 3079 0301jvls@novonordisk.comAnn Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.comMark Joseph Root+45 3079 4211mjhr@novonordisk.comKristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Attachment CA_210412_SafeHarbour
- Zacks
The Zacks Analyst Blog Highlights: Facebook, Adobe, Novo Nordisk, PetroChina and Teladoc Health
The Zacks Analyst Blog Highlights: Facebook, Adobe, Novo Nordisk, PetroChina and Teladoc Health
- Zacks
Top Analyst Reports for Facebook, Adobe & Novo Nordisk
Top Analyst Reports for Facebook, Adobe & Novo Nordisk
